ERBB2 and breast carcinoma: HER2+ breast cancer is well suited to systemic therapy de-escalation due to the development of relatively low-toxicity, high-efficacy targeted therapies beginning with the U.S. Food and Drug Administration approval of adjuvant trastuzumab in 2006.